Medclair AB (NGM:MCLR) Change In Receivables: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:MCLR Medclair AB NGM:MCLR
67 GF Score
Price kr2.89
GF Value kr2.37
Valuation Modestly Overvalued
View Full Analysis

What is Medclair AB Change In Receivables?

Medclair AB NGM:MCLR +0.70% 67 Change In Receivables is kr0.00 Mil as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 67/100 and a GF Value™ of kr2.37 (Modestly Overvalued).

Medclair AB's change in receivables for the quarter that ended in Mar. 2026 was kr0.00 Mil. It means Medclair AB's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

Medclair AB's change in receivables for the fiscal year that ended in Dec. 2025 was kr-0.49 Mil. It means Medclair AB's Accounts Receivable increased by kr0.49 Mil from Dec. 2024 to Dec. 2025 .

Medclair AB's Accounts Receivable for the quarter that ended in Mar. 2026 was kr4.70 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medclair AB's Days Sales Outstanding for the three months ended in Mar. 2026 was 23.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medclair AB's liquidation value for the three months ended in Mar. 2026 was kr16.99 Mil.

Medclair AB  (NGM:MCLR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medclair AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4.703/18.238*91
=23.53

2. In Ben Graham's calculation of liquidation value, Medclair AB's accounts receivable are only considered to be worth 75% of book value:

Medclair AB's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=20.372-10.319+0.75 * 4.703+0.5 * 6.825
=16.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medclair AB Change In Receivables Related Terms

Medclair AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for Medclair AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medclair AB Change In Receivables Chart

Medclair AB Annual Data
Trend Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 -3.81 -0.26 -1.01 -0.49

Medclair AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGM:MCLR
67GF Score
Medclair AB NGM:MCLR
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medclair AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr0.00 Mil mean?
Medclair AB (NGM:MCLR) has a Change In Receivables of kr0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Medclair AB and its competitors.
Is Medclair AB's Change In Receivables too high?
Medclair AB's current Change In Receivables is kr0.00 Mil. Overall, Medclair AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Change In Receivables compare to ABT and SYK?
Medclair AB's Change In Receivables of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Medclair AB and its competitors. Medclair AB's current Change In Receivables is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.37, compared to a current price of kr2.89 — trading 21.9% above its estimated fair value. The current Change In Receivables is kr0.00 Mil. Medclair AB's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Change In Receivables is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medclair AB (NGM:MCLR) Overvalued in 2026?

Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued. The current stock price of kr2.89 is trading 21.9% above its estimated GF Value™ of kr2.37. GuruFocus considers Medclair AB to be Modestly Overvalued.

Key valuation signals for NGM:MCLR:

  • Change In Receivables: kr0.00 Mil
  • GF Value™: kr2.37 vs. price of kr2.89 (21.9% above fair value)
  • GF Score™: 67/100

No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medclair AB Business Description

Address Fraktflygargatan 1, Stockholm, SWE, 128 30
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
67GF Score

Get the complete analysis for NGM:MCLR

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.89
Price
kr2.37
GF Value